Payment overview · 2025
General Payments
$109.43
6 reported records · 5 companies
Healthcare provider profile · identity verified
Gregory T. Stephens, M. D.
Allopathic & Osteopathic Physicians|Family Medicine · MECHANICSVILLE, VA · NPI 1255306460
Verified facts
What the public records show
CMS Open Payments records show Gregory T. Stephens, M. D. received $109.43 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.95 | 28.3% | 2 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $28.88 | 26.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 17.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.16 | 14.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.59 | 13.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $90.58 | 5 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.95 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.95 | 2 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $28.88 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 456 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 308 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 207 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 56 |
| Omeprazole | Omeprazole | 182 | 57 |
| Lisinopril | Lisinopril | 177 | 51 |
| Metformin Hcl | Metformin Hcl | 165 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 163 | 42 |
| Simvastatin | Simvastatin | 152 | 42 |
| Losartan Potassium | Losartan Potassium | 140 | 44 |
| Sertraline Hcl | Sertraline Hcl | 133 | 37 |
| Trazodone Hcl | Trazodone Hcl | 108 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 30 |
| Farxiga | Dapagliflozin Propanediol | 73 | 15 |
| Tramadol Hcl | Tramadol Hcl | 69 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 65 | 20 |
| Eliquis | Apixaban | 64 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 20 |
| Metformin Hcl Er | Metformin Hcl | 62 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 17 |
| Glimepiride | Glimepiride | 59 | 19 |
| Montelukast Sodium | Montelukast Sodium | 59 | 17 |
| Ozempic | Semaglutide | 59 | 12 |
| Furosemide | Furosemide | 56 | 20 |
| Gabapentin | Gabapentin | 56 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 27 |
| Famotidine | Famotidine | 52 | 18 |
| Allopurinol | Allopurinol | 51 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 15 |
| Potassium Chloride | Potassium Chloride | 49 | 14 |
| Prednisone | Prednisone | 49 | 27 |
| Alprazolam | Alprazolam | 47 | suppressed |
| Atenolol | Atenolol | 47 | 14 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Valsartan | Valsartan | 46 | 16 |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | 13 |
| Ezetimibe | Ezetimibe | 41 | 14 |
| Carvedilol | Carvedilol | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 11 |
| Buspirone Hcl | Buspirone Hcl | 32 | 19 |
| Finasteride | Finasteride | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | 13 |
| Clonidine | Clonidine | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $109.43 · 6 records | ABBVIE INC. | ABRYSVO, COMIRNATY, ImmunoCAP, JARDIANCE, PREVNAR 20, QULIPTA, UBRELVY, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error